Metabolic dysfunctions associated with stetotic liver disease

Abstract

Metabolic Dysfunction-Associated Stetotic Liver Disease (MASLD) is a significant cause of chronic liver disease, affecting 30% of the global population, and can progress to severe conditions like fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Traditional treatments are limited, so a more integrated approach is necessary. Early identification and modification of risk factors are crucial for preventing complications. MASLD is a major public health concern, causing liver-related morbidity and mortality. A clear assessment and referral pathway is needed for managing severe cases, with lifestyle interventions and cardiovascular risk management being key components. While no specific medication is approved, novel antihyperglycemic drugs show promise. Management should also address liver disease progression, sarcopenia, and adjustments to medications for diabetes and metabolic conditions. The term MASLD replaced Non-Alcoholic Fatty Liver Disease (NAFLD) in 2023 to highlight the disease's connection to metabolic dysfunction. Altered metabolic function can lead to both cardiovascular and liver diseases. Traditional treatment approaches have focused on individual organs, resulting in siloed care. However, because metabolic dysfunction affects the entire body, a more integrated approach involving multiple medical specialists is needed to improve patient outcomes. It suggests that addressing the underlying disease process, rather than solely targeting the cardiovascular or liver-specific issues could be more effective.